These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 18680689)

  • 21. Antiretroviral therapy and dyslipidaemia: unlocking the code.
    Mallon PW
    PLoS Med; 2006 Mar; 3(3):e85. PubMed ID: 16420104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update.
    Cressey TR; Lallemant M
    Infect Genet Evol; 2007 Mar; 7(2):333-42. PubMed ID: 17045554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenetics of the metabolic disturbances and atherosclerosis associated with antiretroviral therapy in HIV-infected patients.
    Veloso S; Peraire J; Viladés C; López-Dupla M; Escoté X; Olona M; Garcia-Pardo G; Gómez-Bertomeu F; Soriano A; Sirvent JJ; Vidal F
    Curr Pharm Des; 2010 Oct; 16(30):3379-89. PubMed ID: 20687887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV pharmacogenetics in clinical practice: recent achievements and future challenges.
    Tozzi V; Libertone R; Liuzzi G
    Curr HIV Res; 2008 Nov; 6(6):544-54. PubMed ID: 18991620
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
    Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rolling out Efavirenz for HIV Precision Medicine in Africa: Are We Ready for Pharmacovigilance and Tackling Neuropsychiatric Adverse Effects?
    Masimirembwa C; Dandara C; Leutscher PD
    OMICS; 2016 Oct; 20(10):575-580. PubMed ID: 27627692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacogenetic considerations in the treatment of HIV.
    Mattevi VS; Tagliari CF
    Pharmacogenomics; 2017 Jan; 18(1):85-98. PubMed ID: 27976978
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacogenomics of Antiretroviral Drug Metabolism and Transport.
    Yu ZJ; Mosher EP; Bumpus NN
    Annu Rev Pharmacol Toxicol; 2021 Jan; 61():565-585. PubMed ID: 32960701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antiretroviral drugs in HIV-infected children.
    Viganò A; Manfredini V; Penagini F; Giacomet V; Zuccotti GV
    Pharmacol Res; 2011 Jul; 64(1):1-3. PubMed ID: 21255650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.
    Neely MN; Rakhmanina NY
    Clin Pharmacokinet; 2011 Mar; 50(3):143-89. PubMed ID: 21294595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toxicities of antiretroviral therapy in children.
    Nwaobasi E; Oleske JM
    AIDS Read; 2006 Oct; 16(10):537-40, 544-6,549-50, 552-4. PubMed ID: 17096472
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hypersensitivity syndrome--the role of pharmacogenetics for prediction of efficacy and safety of antiretroviral therapy in patients with HIV/AIDS].
    Cholewińska G
    Przegl Epidemiol; 2008; 62(1):149-54. PubMed ID: 18536238
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
    De Luca A; Hamers RL; Schapiro JM
    J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in pharmacogenomics of antiretrovirals: an update.
    Ma Q; Brazeau D; Forrest A; Morse GD
    Pharmacogenomics; 2007 Sep; 8(9):1169-78. PubMed ID: 17924832
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential for new antiretrovirals to address unmet needs in the management of HIV-1 infection.
    Moyle G; Gatell J; Perno CF; Ratanasuwan W; Schechter M; Tsoukas C
    AIDS Patient Care STDS; 2008 Jun; 22(6):459-71. PubMed ID: 18479200
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New antiretroviral drugs and approaches to HIV treatment.
    Paredes R; Clotet B
    AIDS; 2003; 17 Suppl 4():S85-96. PubMed ID: 15080184
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.
    Vidal F; Domingo P; Viladés C; Peraire J; Arnedo M; Alcamí J; Leal M; Villarroya F; Gatell JM
    Expert Opin Drug Metab Toxicol; 2011 Nov; 7(11):1365-82. PubMed ID: 21999362
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
    Sturt AS; Dokubo EK; Sint TT
    Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.